All News

guidelines.recommendations.jpg

2022 EULAR Recommendations for ANCA-associated Vasculitis

Jack Cush, MD

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Read Article
Pills_0.jpg

Polypharmacy Increased in Psoriatic Arthritis

Jack Cush, MD

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.

Read Article
DLE discoid lupus

A Pilot Trial of Anifrolumab in Discoid Lupus

Jack Cush, MD

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Read Article
DMARDs,biologics,RA

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

Carpal Tunnel - Steroid injection vs. Night Splinting

Jack Cush, MD

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Read Article
RheumNow Podcast square

Big Time Vasculitis (3.10.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?

Read Article
myositis.jpg

Long-Term Survival of Idiopathic Inflammatory Myopathies

Jack Cush, MD

A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.

Read Article
Could MTX every other week dosing be an option in patients with stable disease..? #RNL2023 https://t.co/EZRdQnuXjy
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow https://t.co/DirAovm1AX
Robert B Chao, MD doctorRBC ( View Tweet)
✅ RheumNow Live 2023 #RNL2023 @RheumNow Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq
Laurent ARNAUD Lupusreference ( View Tweet)
#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer ⁦@RheumNow⁩ #RNL2023 https://t.co/i0LZoQuK0w
Janet Pope Janetbirdope ( View Tweet)
Do you stop MTX on patients on bDMARD? MTX decrease anti-drug antibodies on patients on infliximab - increases drug duration. Similar seen with new combination usage with pelogloticase Joel Kremer MD #RhuemNow @RheumNow https://t.co/8UrGZaFStA
Eric Dein ericdeinmd ( View Tweet)
How do you wean MTX? Consider every other week dosing as options - supported by 2 randomized studies from 1995 and 1999 Option to lower weekly dosing in patients that want to take less often Joel Kremer #RNL2023 @RheumNow https://t.co/3GMdn3lLhy
Eric Dein ericdeinmd ( View Tweet)
Do and don’t around MTX , Dr.Kremer approach to MTX #RNL2023 ⁦@RheumNow⁩ https://t.co/dXLQ0epsp4
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/cmwGEWHQEO
Eric Dein ericdeinmd ( View Tweet)
JAKinib safety takeaways - avoid in older population > 65 yo, malignancy, CV risk, VTE risk - appropriate in younger pts without VTE/CVD risk factors #RNL2023 @RheumNow https://t.co/5i1bRqqr7g
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 @RheumNow Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/AZDKShOPbU
Eric Dein ericdeinmd ( View Tweet)
10 yr study of 390 RA pts, of whom 160 (41%) had MTX-related gastrointestinal intolerance (GIS); meaning they D/C MTX and had EGD - H. pylori was significantly higher inMTX GIS pts; such pts had 3 fold higher odds of Rx w/ biologics or JAKi's https://t.co/RvrUErHyWe https://t.co/ea8Kq42oqW

Links:

Dr. John Cush RheumNow ( View Tweet)
Annually acetaminophen is responsible for 112 000 US poison center calls, 59000 emergency department visits, and 38000 hospitalizations. Of more concern, it is the leading cause of acute liver failure in the US and other high-income countries https://t.co/5AtQAD1dKu https://t.co/ntZ8dD1srz

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×